ReviewCANCER

Oil for the cancer engine: The cross-talk between oncogenic signaling and polyamine metabolism

See allHide authors and affiliations

Science Advances  24 Jan 2018:
Vol. 4, no. 1, eaar2606
DOI: 10.1126/sciadv.aar2606

Figures

  • Fig. 1 Regulation and targeting of polyamine metabolism.
  • Fig. 2 Molecular and biological consequences of polyamines.
  • Fig. 3 Oncogenic signaling regulating polyamine metabolism.

Tables

  • Table 1 Table highlighting polyamine metabolism targeting inhibitors tested in preclinical and/or clinical studies.

    PA, polyamine.

    Preclinical studies
    InhibitorTargetCancerReference
    DFMOODC1Prostate cancer(101, 102)
    Pancreatic cancer(103)
    Breast cancer(104, 105)
    Colon cancer(106)
    Neuroblastoma(107, 108)
    Live cancer(109)
    MGBCPAMD1Prostate cancer(102)
    Leukemia(110)
    Osteosarcoma(111)
    Melanoma(112)
    SAM486A (CGP48664)AMD1Bladder cancer, melanoma(113)
    Neuroblastoma(107)
    ORI 1202*PA transporterBreast cancer(105)
    Prostate cancer(101)
    BENSpm/DENSpm# [N (1),N (11)bis(ethyl)norspermine]PA analogBreast cancer(114)
    PG11047/CGC-11047#PA analogLung cancer(115)
    Prostate and lung cancer(116)
    Pediatric tumors(117)
    SL11144/ CGC-11144PA analogBreast cancer(118)
    Clinical trials
    InhibitorTargetCancer typeReference
    DFMOODC1Prostate cancer(119)
    Lung and colon cancer(120)
    MGBCPAMD1Prostate cancer(119)
    SAM486A (CGP48664)AMD1Solid tumors(18, 19, 121, 122)
    Non-Hodgkin’s lymphoma(121, 123)
    BENSpm/DENSpm# [N1,N11-bis(ethyl)norspermine]PA analogSolid tumors(124)
    Non–small cell lung cancer(125)
    Metastatic breast cancer(126)
    DEHSPM (N1,N14-diethyl homospermine)PA analogSolid tumors(127)
    PG11047/CGC-11047#PA analogSolid tumorswww.clinicaltrials.gov, NCT00705653
    Solid tumors and lymphomawww.clinicaltrials.gov, NCT00705874

    *In combination with other inhibitors.

    #As a single agent and in combination with chemotherapy.

    Navigate This Article